Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65+
SponsorWladimir MAUHIN, Dr

About this trial

Fabry disease is a rare genetic disorder affecting 1 in 10,000 individuals, leading to complications such as chronic pain, heart and kidney failure, and strokes, ultimately impacting life expectancy. People with this disease are increasingly being diagnosed later in life, around the age of 65, as the condition progresses slowly with irreversible organ damage. The effectiveness of treatments for Fabry disease remains controversial, but early initiation is recommended for long-term benefits. Despite the high cost and inconvenience of treatments, there is limited research on their efficacy in older people or on the quality of life for those aged 65 and over with Fabry disease. This study aims to assess the quality of life in this age group both with and without treatment over a period of 5 years to determine the benefits of treatment beyond the age of 65.

Eligibility criteria

Qualifiers

Men and women aged 65 and over with a diagnosis of Fabry disease with, for men, a proven alpha-galactosidase A deficiency or an identified pathogenic GLA genetic variant, and for women, an identified pathogenic GLA variant.

Minimum work-up available: ECG, 24h holterECG, cardiac ultrasound, creatinemia, proteinuria and/or microalbuminuria.

Have received written and oral information about the protocol and have not expressed any opposition to participating in the study.

Affiliated to a social security scheme or entitled to benefits (excluding AME).

Disqualifiers

Inability to understand the information provided,

Under guardianship, curatorship or safeguard of justice,

Under restraint or deprived of liberty by judicial or administrative decision.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

100 Participants
are grouped into 1 trial group

Sponsors and collaborators

Wladimir MAUHIN, Dr

Lead sponsor

Groupe Hospitalier Diaconesses Croix Saint-Simon

Sponsor institution

University Hospital, Angers

Collaborator

University Hospital, Bordeaux

Collaborator

Centre Hospitalier Bretagne Atlantique

Collaborator

Centre Hospitalier Universitaire de Caen

Collaborator

University Hospital, Clermont-Ferrand

Collaborator

Centre Hospitalier Universitaire Dijon

Collaborator

University Hospital, Lille

Collaborator

University Hospital, Limoges

Collaborator

University Hospital, Marseille

Collaborator

Nantes University Hospital

Collaborator

Hôpital Necker-Enfants Malades

Collaborator

Rennes University Hospital

Collaborator

University Hospital, Tours

Collaborator

Hôpital Raymond Poincaré

Collaborator

University Hospital, Rouen

Collaborator

Hospital, Vannes

Collaborator

University Hospital, Brest

Collaborator

University Hospital, Grenoble

Collaborator

University Hospital, Strasbourg

Collaborator

Hospices Civils de Lyon

Collaborator

Centre Hospitalier de la côte Basque

Collaborator

University Hospital, Montpellier

Collaborator

Centre Hospitalier Universitaire de Nice

Collaborator